| Literature DB >> 32670417 |
Miroslaw Janczura1, Jerzy Dropinski2, Anna Gielicz2, Katarzyna Kotula-Horowitz3, Teresa Iwaniec2, Andrzej Stanisz4, Rafal Rosa5, Teresa B Domagala6.
Abstract
BACKGROUND: The present study investigated the relationships between psychological stress indices and oxidative stress marker, also when combined with emergent insulin resistance (IR), in the non-diabetic, middle-aged subjects, exposed to frequent/chronic psychological stressors.Entities:
Keywords: Cortisol; Insulin resistance; Oxidative stress; Psychological stress
Year: 2020 PMID: 32670417 PMCID: PMC7346531 DOI: 10.1186/s13098-020-00566-8
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Characteristics of the study subjects, as stratified by insulin resistance status
| Variable | Insulin resistance | No insulin resistance | p |
|---|---|---|---|
| N (F) | 122 (7) | 112 (12) | |
| Age; years | 41.00 (39.62, 42.38) | 40.00 (38.52, 41.47) | 0.39 |
| Metabolic syndrome; n (%) | 86 (67.71) | 24 (21.42%) | < 0.0001 |
| Atherogenic dyslipidemia; n (%) | 36 (28.35) | 9 (8.03) | 0.0001 |
| FRS | 5.40 (4.26, 6.53) | 3.20 (2.22, 4.17) | 0.0001 |
| BMI; kg/m2 | 31.44 (30.55, 32.32) | 27.75 (26.95, 28.55) | < 0.0001 |
| W/H ratio | 0.977 (0.973, 0.990) | 0.91 (0.895, 0.926) | < 0.0001 |
| Overweight; n (%) | 44 (34.64) | 58 (51.78) | 0.01 |
| Obesity; n (%) | 78 (61.42) | 25 (23.21) | < 0.0001 |
| Stable CHD, n (%) | 13 (10.23%) | 4 (3.57%) | 0.06 |
| Coronary plaque; n (%)a | 32 (33.33) | 13 (21.31) | 0.11 |
| Hypertension; n(%) | 87 (71.31) | 49 (43.75) | < 0.0001 |
| Current smoking; n (%) | 42 (33.07) | 35 (31.25) | 0.98 |
| Total cholesterol; mmol/L | 5.40 (5.18, 5.61) | 5.05 (4.81, 5.28) | 0.08 |
| LDL cholesterol; mmol/L | 3.12 (2.94, 3.30) | 2.99 (2.80, 3.17) | 0.32 |
| HDL cholesterol; mmol/L | 1.20 (1.15, 1.24) | 1.29 (1.25, 1.34) | 0.01 |
| Triglycerides, mmol/L | 2.05 (1.68, 2.42) | 1.34 (1.05, 1.62) | < 0.001 |
| Glucose; mmol/L | 5.40 (5.24, 5.57) | 5.10 (4.99, 5.20) | < 0.0001 |
| ALT; U/L | 44.00 (40,49, 49.50) | 38.00 (32,82, 39.77) | 0.002 |
| AST; U/L | 34.00 (31.89, 36.90) | 30.00 (28.07, 31.37) | 0.002 |
| Total bilirubin; µmol/L | 12.00 (10.42, 13.57) | 13.00 (11.53, 14.46) | 0.16 |
| Uric acid; µmol/L | 378.00 (359.61, 396.38) | 334.50 (315.95, 353.04) | < 0.0001 |
| Serum creatinine; µmol/L | 91.00 (87.78, 94.21) | 89.00 (85.84, 92.15) | 0.30 |
| SBP; mm Hg | 135.00 (131.40, 138.66) | 120.00 (115.92, 124.07) | < 0.0001 |
| DBP; mm Hg | 85.00 (82.65, 87.35) | 80.00 (76.56, 82.43) | 0.0009 |
| cIMT; mm | 0.56 (0.550, 0.571) | 0.54 (0.535, 0.547) | 0.001 |
| FMD; % | 7.08 (6.30, 7.85) | 7.57 (6.75, 8.38) | 0.31 |
| CRP; mg/L | 1.29 (1.229, 1.36) | 0.88 (0.53, 1.23) | 0.0001 |
| TNF-α; pg/mL | 0.92 (0.90, 0.94) | 0.82 (0.74, 0.89) | 0.02 |
| Fibrinogen; g/L | 3.30 (3.11, 3.48) | 3.20 (3.01, 3.38) | 0.61 |
| Insulin; µIU/mL | 23.82 (20.10, 27.54) | 11.37 (10.55, 12.18) | < 0.0001 |
| HOMA-IR | 3.02 (2.78, 3.26) | 1.46 (1.35, 1.56) | < 0.0001 |
| Plasma 8-iso-PGF2α; pg/mL | 7.60 (6.55, 8.03) | 6.39 (5.21, 6,56) | 0.04 |
| Urine cortisol; ng/mg of creatinine | 119.70 (105.01, 134.40) | 89.80 (76.90, 102.69) | < 0.001 |
| PSS-10 score | 17.00 (15.73, 18.27) | 16.0 (14.86, 17.30) | 0.62 |
| Medications, n (%) | |||
| Aspirin | 1 (0.82) | 5 (4.46) | 0.07 |
| ACEI/ARB | 31 (25.40) | 10 (8.93) | 0.001 |
| β-blocker | 28 (22.95) | 12 (10.71) | 0.01 |
| Ca-blocker | 10 (8.10) | 3 (2.68) | 0.05 |
| Diuretics | 22 (18.03) | 5 (4.46) | 0.001 |
| Lipid-lowering agents | 7 (5.74) | 4 (3.57) | 0.43 |
Data are expressed as no. (%), or median (95% CI)
Framingham Risk Score, 10-year risk of developing coronary heart disease; CHD coronary heart disease, BMI body mass index, W/H waist/hip, FMD flow-mediated dilation, cIMT carotid intima-media thickness, LDL low density lipoprotein, HDL high density lipoprotein, CRP C-reactive protein, 8-iso-PGF 8-iso-prostaglandin F2α, TNF-α tissue necrotic factor-α, SBP (DBP) systolic (diastolic) blood pressure, HOMA-IR the homeostasis model assessment of insulin resistance, PSS perceived stress scale, ALT alanine aminotransferase, AST aspartate aminotransferase
an (%) subjects who underwent computed tomography coronary angiography
Associations between the indices of psychological stress and oxidative stress marker in univariate analyses
| Cortisol | PSS scores | |||
|---|---|---|---|---|
| B (95% CI) | p | B (95% CI) | p | |
| 8-iso-PGF2α | 0.007 (0.0006, 0.014) | 0.03 | 0.139 (0.048, 0.230) | 0.002 |
| Cortisol | – | – | 2.150 (0.202, 4.097) | 0.03 |
B unstandardized coefficient, CI confidence interval, 8-iso-PGF 8-iso-prostaglandin F2α
Associations between the indices of psychological stress and oxidative stress marker with HOMA-IR
| B (95% CI) | p | |
|---|---|---|
| 8-iso-PGF2α | 0.069 (0.016, 0.120) | 0.01 |
| 0.068 (0.007, 0.129) | 0.02# | |
| Cortisol | 0.003 (0.0003, 0.005) | 0.02 |
| 0.002 (− 0.0003, 0.005) | 0.06# | |
| PSS scores | 0.007 (− 0.028, 0.043) | 0.67 |
| − 0.013 (− 0.050, 0.023) | 0.48# |
B unstandardized coefficient, CI confidence interval, HOMA-IR the homeostasis model assessment of IR, 8-iso-PGF 8-iso-prostaglandin F2α
#Multivariate regression model comprised cortisol, PSS score, 8-iso-PGF2α, adjusted for age, sex, and current smoking
Associations of select variables with HOMA-IR in multivariate analysis
| Variable | B (95% CI) | p |
|---|---|---|
| Waist circumference | 0.056 (0.039, 0.074) | < 0.0001 |
| Triglycerides | − 0.531 (− 0.174, 0.069) | 0.39 |
| HDL cholesterol | − 0.597 (− 1.139, − 0.055) | 0.03 |
| SBP | 0.009 (0.00003, 0.018) | 0.04 |
| 8-iso-PGF2α | 0.032 (− 0.013, 0.078) | 0.11 |
| Cortisol | 0.001 (− 0.0007, 0.003) | 0.18 |
Multivariate regression model comprised of the variables whose values, when exceeding the reference range (i.e. abnormal), are the key identification attributes of metabolic syndrome (apart from glucose), cortisol, and 8-iso-PGF2α, adjusted for age, sex, and current smoking
B unstandardized coefficient, CI confidence interval, SBP systolic blood pressure, 8-iso-PGF 8-iso-prostaglandin F2α
Odds ratios for the incidence of insulin resistance
| Variable | OR (95% CI) | p |
|---|---|---|
| 8-iso-PGF2α | 1.103 (1.010, 1.203) | 0.02 |
| 1.011 (1.002, 1.213) | 0.04# | |
| 1.017 (0.922, 1.120) | 0.72¶ | |
| Cortisol | 1.007 (1.002, 1.012) | 0.006 |
| 1.006 (1.001, 1.011) | 0.01# | |
| 1.004 (0.999, 1.010) | 0.08¶ | |
| Atherogenic dyslipidemia | 3.511 (1.634, 7.553) | 0.001 |
| Metabolic syndrome | 6.828 (3.775, 12.354) | < 0.00001 |
OR odds ratio, CI confidence interval, 8-iso-PGF 8-iso-prostaglandin F2α
#Multivariate regression model comprised 8-iso-PGF2α, cortisol, atherogenic dyslipidemia (yes/no), adjusted for age, sex, and current smoking
¶Multivariate regression model comprised 8-iso-PGF2α, cortisol, metabolic syndrome (yes/no), adjusted for age, sex, and current smoking
Odds ratios for insulin resistance relative to metabolic syndrome components, cortisol, and 8-iso-PGF2α
| Variable | OR (95% CI) | p |
|---|---|---|
| Waist circumferencea | 4.966 (2.29, 10.75) | 0.00004 |
| 3.621 (1.602, 8.182) | 0.001# | |
| High blood pressure | 1.860 (0.976, 3.542) | 0.05 |
| 1.940 (0.966, 3.896) | 0.06# | |
| Hypertriglyceridemia | 1.993 (1.063, 3.736) | 0.03 |
| 2.012 (1.025, 3.949) | 0.04# | |
| Low HDL cholesterol | 1.472 (0.706, 3.068) | 0.29 |
| 1.568 (0.726, 3.386) | 0.24# | |
| 8-iso-PGF2α | 1.055 (0.953, 1.168) | 0.29# |
| Cortisol | 1.005 (0.999, 1.100) | 0.10# |
OR odds ratio, CI confidence interval, 8-iso-PGF 8-iso-prostaglandin F2α
#Baseline model, cortisol, and 8-iso-PGF2α adjusted for age, sex, and current smoking
a≥94/80 cm (men/women). Baseline model comprised of metabolic syndrome components, except elevated fasting plasma glucose, as glucose was already included in the HOMA-IR formula